Q2 2024 · 13F-HR
Opaleye Management Inc.holdings as filed
Filed 2024-08-14 · accession 0001493152-24-032150
$437.7M
Reported value
51
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 415858109 | HROW | HARROW HEALTH INC | $83.4M | 19.0% | 3,990,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $40.6M | 9.27% | 2,280,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $36.3M | 8.29% | 5,307,500 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $21.1M | 4.83% | 515,000 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $16.8M | 3.84% | 367,500 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $14.8M | 3.38% | 555,000 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $13.3M | 3.05% | 1,102,500 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $10.8M | 2.46% | 198,500 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $10.7M | 2.45% | 3,455,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $10.4M | 2.39% | 580,000 | Common | SOLE |
| 14888U101 | CPRX | CATALYST PHARMACEUTICALS INC | $9.9M | 2.27% | 640,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $9.1M | 2.08% | 555,700 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $8.9M | 2.03% | 392,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $8.7M | 2.00% | 418,928 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $7.9M | 1.80% | 2,645,000 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $7.9M | 1.80% | 2,395,000 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC' | $7.8M | 1.79% | 1,680,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS INC | $7.3M | 1.66% | 345,750 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $7.2M | 1.64% | 897,000 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $7.0M | 1.59% | 1,580,000 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $6.9M | 1.58% | 412,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $6.4M | 1.47% | 85,000 | Common | SOLE |
| 09075X108 | — | BIODESIX INC | $6.2M | 1.41% | 4,020,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $6.1M | 1.38% | 315,000 | Common | SOLE |
| 98419J206 | XOMA | XOMA CORP DEL | $5.9M | 1.35% | 250,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $5.3M | 1.21% | 2,304,262 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $4.9M | 1.11% | 218,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $4.5M | 1.03% | 59,300 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $4.5M | 1.02% | 865,443 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $4.0M | 0.90% | 8,000,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $3.9M | 0.89% | 325,000 | Common | SOLE |
| 48576UAA4 | — | KARYOPHARM THERAPEUTICS INC | $3.7M | 0.86% | 6,000,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $3.6M | 0.83% | 105,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $3.5M | 0.80% | 3,910,000 | Common | SOLE |
| 528872302 | LXRX | LEXICON PHARMACEUTICALS INC | $3.1M | 0.72% | 1,875,000 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $2.9M | 0.66% | 714,960 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $2.8M | 0.64% | 2,780,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $2.7M | 0.63% | 1,190,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $2.7M | 0.62% | 915,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $2.6M | 0.60% | 1,475,000 | Common | SOLE |
| 55083R104 | — | LYELL IMMUNOPHARMA INC | $2.4M | 0.55% | 1,670,000 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $1.8M | 0.41% | 600,000 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $1.8M | 0.40% | 285,000 | Common | SOLE |
| 48576U106 | KPTIEUR | KARYOPHARM THERAPEUTICS INC | $1.2M | 0.28% | 1,425,000 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $791,250 | 0.18% | 375,000 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $769,500 | 0.18% | 475,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $730,400 | 0.17% | 440,000 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $686,750 | 0.16% | 205,000 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $592,000 | 0.14% | 200,000 | Common | SOLE |
| 01626L105 | — | ALIGOS THERAPEUTICS INC | $441,000 | 0.10% | 1,260,000 | Common | SOLE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $249,150 | 0.06% | 165,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.